This clinical trial is focused on studying the effects of a treatment for Pulmonary Hypertension, a condition where there is high blood pressure in the blood vessels that supply the lungs. The specific type of pulmonary hypertension being studied is related to heart failure with preserved ejection fraction, which means the heart pumps normally but is too stiff to fill properly. The treatment being tested is called sotatercept, also known by its code name MK-7962. Sotatercept is a solution for injection and is designed to help manage this condition.

The purpose of this study is to evaluate the long-term safety and tolerability of sotatercept over a period of up to 42 months. Participants in the study will receive sotatercept through subcutaneous injections, which means the medication is injected under the skin. The study will monitor participants for any adverse events, which are unwanted effects that may occur during the treatment. Additionally, the study will assess changes in participants’ ability to walk a certain distance in six minutes, as well as changes in their heart function and blood pressure in the lungs over time.

This study is an extension of previous research and aims to provide more information on how well sotatercept works and how safe it is for people with pulmonary hypertension. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of the treatment. The study is expected to continue until 2029, allowing researchers to collect comprehensive data on the long-term effects of sotatercept.